Sonus Pharmaceuticals Inc - Current report filing (8-K)
May 09 2008 - 7:40AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
May 6, 2008
SONUS PHARMACEUTICALS, INC.
(Exact name of
Registrant as Specified in Its Charter)
Delaware
|
|
000-21243
|
|
95-4343413
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No)
|
1522 217th Place S.E., Bothell, Washington 98021
(Address of principal executive offices)
(425) 487-9500
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing
On
November 7, 2007, the Company reported on Form 8-K that it had
received a notice from The NASDAQ Stock Market (NASDAQ) indicating that it did
not comply with the minimum $1.00 per share bid price requirement for continued
inclusion under Marketplace Rule 4450(a)(5) (the Rule). Therefore,
in accordance with Marketplace Rule 4450(e)(2), the Company was told that
it had 180 calendar days, or until May 5, 2008, to regain compliance.
The
Company has not regained compliance with the Rule. As a result, on May 6, 2008, the Company
received a determination letter from NASDAQ stating that its common stock would
be delisted unless the Company appeals the delisting determination. The Company intends to appeal NASDAQs
determination to delist its common stock to a NASDAQ Listing Qualifications
Panel. There is no assurance that a
Nasdaq Listing Qualifications Panel will grant the Companys request for
continued listing. During the appeal
process, the Companys common stock will continue to trade on The Nasdaq Global
Market.
The Company issued a press release on May 9,
2008 regarding the determination letter that it received from NASDAQ. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated by reference herein.
Item
9.01
|
|
Financial
Statements and Exhibits.
|
|
|
|
(d)
|
|
Exhibits.
|
|
|
|
|
|
Exhibit 99.1 Press
release issued by Sonus Pharmaceuticals, Inc. on May 9, 2008.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
SONUS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date:
May 9, 2008
|
By:
|
/s/
Alan Fuhrman
|
|
|
Alan
Fuhrman
|
|
|
Senior
Vice President and Chief Financial Officer
|
3
Exhibit Index
Exhibit No.
|
|
Description
|
99.1
|
|
Press
release issued by Sonus Pharmaceuticals, Inc. on May 9, 2008.
|
4
Sonus (NASDAQ:SNUS)
Historical Stock Chart
From Apr 2024 to May 2024
Sonus (NASDAQ:SNUS)
Historical Stock Chart
From May 2023 to May 2024